SCHEMBL826349

SCHEMBL826349

FC(F)(F)c1cc(Cl)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.52
LOX P28300 1/20 0.50
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
NOTUM Q6P988 1/20 0.43
IDO1 P14902 1/20 0.43
DDR1 Q08345 1/20 0.39
AR P10275 1/20 0.39
CA2 P00918 1/20 0.39
CHKA P35790 1/20 0.39
GAA P10253 1/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
KCNQ2 O43526 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAP4K4 O95819 1/20 0.36
ADRB1 P08588 1/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3745557 0.98 LOXL2 (0.53) LOXL2LOXSMARCA2SMARCA4NOTUM
SCHEMBL1274473 0.84 CYP3A4 (0.46) LOXL2LOXSMARCA2SMARCA4GAA
SCHEMBL16369760 0.83 LOXL2 (0.36) LOXL2LOXSMARCA2SMARCA4DDR1
SCHEMBL31543170 0.83 LOXL2 (0.36) LOXL2LOXSMARCA2SMARCA4DDR1
SCHEMBL29006579 0.79 CYP3A4 (0.38) SMARCA2SMARCA4ALDH1A1PTGS1PTGS2
SCHEMBL29850129 0.78 LOXL2 (0.37) LOXL2LOXSMARCA2SMARCA4DDR1
SCHEMBL29850107 0.78 LOXL2 (0.44) LOXL2LOXSMARCA2SMARCA4DDR1
SCHEMBL2739657 0.77 LMNA (0.40) IDO1ALDH1A1HSD17B10
SCHEMBL25011789 0.77 LOXL2 (0.33) LOXL2LOXSMARCA2SMARCA4
SCHEMBL2642373 0.74 LOXL2 (0.53) LOXL2LOXSMARCA2SMARCA4NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
EP-4733303-A1 MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF Haisco Pharmaceutical Group Co., Ltd. (CN) 2026-04-29 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
US-12545682-B2 Heterocyclic derivatives as P2X7 receptor antagonists BREYE THERAPEUTICS APS (DK) 2026-02-10 US disclosed
US-12528783-B2 PqsR inverse agonists HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2026-01-20 US disclosed
US-20260015743-A1 MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS WISCONSIN ALUMNI RES FOUND (US) 2026-01-15 US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 EP disclosed
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2026-01-01 US disclosed
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 US disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 EP disclosed
EP-1230225-A2 PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-08-14 EP disclosed
WO-2001032632-A2 PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-05-10 WO disclosed
US-4474599-A 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents THE DOW CHEMICAL COMPANY (US) 1984-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015743-A1 MEDIATED HYDROGEN ANODE FOR USE IN REDUCTIVE ELECTROSYNTHESIS HAO2, HACL2, HVCN1 LOXL2 2103/4885LOX 3273/4885SMARCA2 4151/4885
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 LOXL2 4319/4885LOX 2562/4885SMARCA2 4603/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 LOXL2 739/4885LOX 749/4885SMARCA2 4264/4885
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 LOXL2 3892/4885LOX 4221/4885SMARCA2 2919/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 LOXL2 2853/4885LOX 2507/4885SMARCA2 3403/4885
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN1B LOXL2 1813/4885LOX 1806/4885SMARCA2 4295/4885
US-12545682-B2 Heterocyclic derivatives as P2X7 receptor antagonists P2RX7, P2RX3, P2RX1 LOXL2 1829/4885LOX 1268/4885SMARCA2 4760/4885
US-12528783-B2 PqsR inverse agonists OPRL1, MTNR1A, QRFPR LOXL2 1220/4885LOX 3241/4885SMARCA2 4253/4885
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 LOXL2 3308/4885LOX 1715/4885SMARCA2 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.